Unleash the value of Next-Generation Sequencing (NGS) in cancer drug discovery and development in Asia

Allen Lai
ACT Genomics, Singapore

Coupled with the availability of molecular therapeutic targeting genomically defined population, Next-Generation Sequencing (NGS) based multiplexed genomic profiling has created a growing interest among cancer specialists and pharmaceutical companies. Among all, using the adequate technology platform to identify the right genomic biomarker and provide treatment options is pivotal in drug discovery and development, as well as clinical decision making. There is little doubt that the interest has been prompted by advances in our understanding of disease, improvements in NGS platforms and accumulating paradigms of benefit. However, such shift towards precision medicine requires significant changes in healthcare systems, such as regulatory issues, multidisciplinary collaboration in a traditionally conservative and siloed health system. There is much opportunity to pioneer the development of precision medicine, particularly in the growing markets of Asia, where there is a dearth of expertise and quality and which many large organizations have as secondary areas of development. In this talk, Allen Lai will walk the audience through the evolution of cancer precision medicine in the search of biomarkers, and the impact to cancer management in Asia, as well as business growth potential.

Biography

Allen Lai is now the regional managing director of ACT Genomics, Singapore, strategizing corporate development, planning and execution of cancer genomics clinical & research projects in Southeast Asia. He holds several high key profile roles as Advisor Board of ISPOR Asia Consortium, President of ISPOR Singapore and concurrently Senior Consultant, Ministry of Health and Social Welfare, Taiwan. He received his PhD and MPA, from Lee Kuan Yew School of Public Policy, National University of Singapore, M.Sc. (Preventive Medicine) from National Taiwan University and M.D. from Chung Shan Medical Dental University, Taiwan. He was the principal consultant at IMS Health Asia, and the director of Institute of Health Economics & Management and the academic director of MSc Management of Health Industries in ESSEC Business School.

allenlai@actgenomics.com

Notes: